A study shows that high levels of negatively charged lipids can lock growth receptors into an overactive state, driving ...

Palazestrant’s mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen ...

Cantargia AB (Publ) (Nasdaq Stockholm:CANTA) today reported that the rationale and study design of the phase 1b/2 clinical trial investigating nadunolimab in combination with immune-checkpoint ...

Soley Therapeutics, a biotechnology company advancing novel therapeutics informed by integrated cell stress biology, today announced the presentation of new preclinical data at the American ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treat ...

When an axolotl loses a leg, it grows back. Bone, muscle, nerves, skin, even the individual digits return in roughly the ...

In patients developing end-stage liver disease, the damage has become too severe for the liver's normally extraordinary regenerative ...

NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) for improving outcomes for cancer patients, today announced that two poster ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs ...

Depth-of-response measures, including MRD and symptom endpoints, reinforced broad clinical benefit beyond PFS, supporting consideration as a new second-line standard for eligible patients. Infection ...